PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease (External link) Category: News & Announcements 2022By PharmAust03/10/2022Related postsFireside chat with Dr Kim23/12/2022PharmAust Canine Trial Update20/12/2022PharmAust Receives R&D Tax Incentive Refund12/12/2022MND Trial Completes Enrolment of First Patient Cohort02/12/2022PhamAust Webinar17/11/2022PhamAust AGM 202211/11/2022
